Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 25 microgram/ml - injection, solution - excipient ingredients: ethanol; propylene glycol; citric acid; dibasic sodium phosphate; water for injections - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - inhaler - salbutamol as sulfate 100 mcg/dose - salbutamol - salbutamol - ventolin inhaler cfc free is a short-acting (4 to 6 hour) bronchodilator with fast (within 5 minutes) onset in reversible airways obstruction. it is particularly suitable for the relief and prevention of asthma symptoms it should be used to relieve symptoms when they occur, and to prevent them in those circumstances recognized by the patient to precipitate an asthma attack (e.g. before exercise or unavoidable allergen exposure).ventolin inhaler cfc free is particularly valuable as relief medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled corticosteroid therapy.

European Union - English - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - dalbavancin hydrochloride - soft tissue infections; skin diseases, bacterial - antibacterials for systemic use, - treatment of acute bacterial skin and skin structure infections (absssi) in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 250 microgram - tablet, uncoated - excipient ingredients: magnesium stearate; rice starch; lactose monohydrate; oxidised maize starch; hydrolysed maize starch - congestive heart failure - sigmaxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. sigmaxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because sigmaxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - sigmaxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 0.0625 microgram - tablet, uncoated - excipient ingredients: lactose monohydrate; rice starch; magnesium stearate; hydrolysed maize starch; povidone; indigo carmine; oxidised maize starch - congestive heart failure - sigmaxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. sigmaxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because sigmaxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - sigmaxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - triamcinolone acetonide, quantity: 40 mg/ml - injection, suspension - excipient ingredients: benzyl alcohol; sodium chloride; polysorbate 80; carmellose sodium; water for injections; sodium hydroxide; hydrochloric acid - intramuscular: the intramuscular administration of kenacort-a 40 (sterile triamcinolone acetonide suspension usp) is indicated for systemic corticosteroid therapy in such conditions as allergic diseases, dermatoses, or generalised rheumatoid arthritis and other connective tissue disorders. intramuscular administration is particularly valuable in such conditions where oral corticosteroid therapy is not feasible. intra-articular: kenacort-a 40 injection is indicated for intra-articular or intrasynovial administration and for injections into tendon sheaths as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; acute gouty arthritis; epicondylitis; acute non-specific tenosynovitis; post-traumatic osteoarthritis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 50 microgram/ml - oral liquid - excipient ingredients: methyl hydroxybenzoate; dibasic sodium phosphate heptahydrate; sucrose; citric acid; ethanol; propylene glycol; quinoline yellow; purified water; flavour - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenytoin, quantity: 50 mg - tablet, chewable - excipient ingredients: quinoline yellow; saccharin sodium; magnesium stearate; purified talc; sunset yellow fcf; flavour; maize starch; sucrose - dilantin is indicated for the control of grand mal and psychomotor seizures. dilantin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, dilantin frequently improves the mental condition and outlook of epileptic patients and there is also increasing evidence that dilantin is valuable in the prevention of seizures occurring during or after neurosurgery. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenytoin sodium, quantity: 100 mg - capsule, hard - excipient ingredients: gelatin; magnesium stearate; erythrosine; purified talc; titanium dioxide; sunset yellow fcf; carbon black; lactose monohydrate; maize starch; sucrose - dilantin is indicated for the control of grand mal and psychomotor seizures. dilantin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, dilantin frequently improves the mental condition and outlook of epileptic patients and there is also increasing evidence that dilantin is valuable in the prevention of seizures occurring during or after neurosurgery. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenytoin sodium, quantity: 30 mg - capsule, hard - excipient ingredients: magnesium stearate; purified talc; gelatin; carbon black; titanium dioxide; lactose monohydrate; maize starch; sucrose - dilantin is indicated for the control of grand mal and psychomotor seizures. dilantin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, dilantin frequently improves the mental condition and outlook of epileptic patients and there is also increasing evidence that dilantin is valuable in the prevention of seizures occurring during or after neurosurgery. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration).